Core Viewpoint - Aifang Bio has completed a multi-million yuan Series A financing round, which will support its R&D in the IVD field and assist in market expansion and team optimization [1][2]. Company Overview - Aifang Bio, established in 2020 and headquartered in Changsha, is a national high-tech enterprise focusing on the R&D, production, and sales of tumor pathology diagnostic reagents. It is recognized as a specialized and innovative small and medium-sized enterprise and a pilot enterprise for intelligent manufacturing in Changsha [2]. - The company has over 7,000 square meters of R&D and production laboratories, has obtained 20 authorized patents, and has multiple invention patents pending [2]. Main Products and Technologies - Aifang Bio's product line includes the R&D and production of antibodies and pathological staining reagents, featuring over 3,400 rabbit monoclonal research antibodies, more than 400 IVD-grade immunohistochemical antibodies, and over 100 IVD pathological staining reagents [3]. - The core product is the mIHC multi-fluorescence staining and data AI advanced analysis solution, which allows for 30 markers and 31 colors in staining, overcoming traditional staining limitations. This platform integrates advanced data AI analysis algorithms and software for rapid and accurate data analysis, providing data visualization for researchers [3].